Lactoferrin controllable assembly of DNA tetrahedron as well as preparation and application of lactoferrin controllable assembly
By constructing the DNA tetrahedral framework and connecting it with the lactoferrin aptamer, a lactoferrin controllable assembly of the DNA tetrahedral was formed, which solved the problem of immune imbalance caused by high lactoferrin dose and achieved low-dose and efficient immune activation. It enhances the effect of tumor immunotherapy and reduces the dosage of chemotherapy drugs.
Patent Information
- Application Number
- CN202411197625.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-06
AI Technical Summary
When used as an immune adjuvant in tumor immunotherapy, the high dose can easily cause immune factor storms, leading to immune imbalance and high toxicity. It is urgently necessary to develop anti-tumor immune adjuvant with low toxicity and strong immune effects.
By constructing a DNA tetrahedral framework and connecting it with a lactoferrin aptamer, a lactoferrin controllable assembly of the DNA tetrahedral is formed, and free lactoferrin is fixed using its precise structure to form a stable spatial structure, thereby reducing the Dosage and increase its immune activity.
It significantly reduced the dosage of lactoferrin, improved its antigen presentation ability and immune activation effect on macrophages, enhanced the effect of tumor immunotherapy, and reduced the dosage of drug when combined with chemotherapy drugs, expanded the dosage of lactoferrin. Application scope of tumor immunotherapy.
Smart Images

Figure CN119074913A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a DNA tetrahedron lactoferrin controllable assembly, and also relates to the preparation and application of the DNA tetrahedron lactoferrin controllable assembly. Background Art
[0002] Anti-tumor immunotherapy generally involves the activation of macrophages and dendritic cells. Macrophages are phagocytic cells that participate in innate and acquired immunity in the body. Their main function is to phagocytose and digest pathogens or dead cells and activate the immune system. In the tumor microenvironment, macrophages mostly show an immunosuppressive M2 phenotype. Under the stimulation of immune adjuvants, macrophages in the tumor microenvironment polarize into the M1 phenotype that is beneficial to tumor treatment, release inflammatory cytokines, enhance antigen presentation and phagocytic abilities, and thus curb tumor growth. Dendritic cells (DC) are the most powerful professional antigen-presenting cells in the body. They can efficiently ingest, process, and present antigens. Immature DCs have strong migration abilities, and mature DCs can effectively activate naive T cells, which are at the center of initiating, regulating, and maintaining immune responses.
[0003] Immune adjuvants are referred to as adjuvants, that is, non-specific immunopotentiators, which refer to auxiliary substances that can enhance the body's immune response to antigens or change the type of immune response when injected into the body together with antigens or in advance. The development of immune adjuvants is extremely important in the field of tumor immunotherapy. On the one hand, mainstream tumor treatment methods, such as chemotherapy and radiotherapy, have large toxic side effects, while immune adjuvants have lower toxic side effects. On the other hand, immunotherapy based on immune checkpoint inhibitors is also subject to the constraints of immune tolerance, and immune adjuvants can be used in combination with a variety of therapies to improve the effects of chemotherapy, radiotherapy and immunotherapy, enhance the body's immune response, and prolong the survival time of cancer patients. At present, there are only a handful of immune adjuvants used in tumor immunotherapy, and there is an urgent need to develop anti-tumor immune adjuvants with low toxicity and strong immune effects.
[0004] Lactoferrin (LF) is an iron-binding glycoprotein in the transferrin family with immune activity. It regulates host defense by stimulating the immune system and balancing pathogen-induced inflammation. Lactoferrin can stimulate the physiological function of immune activity and has the prospect of developing immune adjuvants. However, the use of LF as an immune adjuvant requires high concentration, which easily causes the risk of immune factor storm in vivo. At the same time, lactoferrin itself also acts as a warning factor to bridge the innate and acquired immunity of the human body. Large-scale use will lead to the risk of human immune imbalance. Therefore, for the development of lactoferrin immune adjuvants, reducing the dose and improving its activity in vivo is a difficulty that needs to be solved urgently. Summary of the invention
[0005] Purpose of the invention: The purpose of the present invention is to provide a DNA tetrahedron controllable lactoferrin assembly, which utilizes the precise structure of the DNA tetrahedron to fix free lactoferrin at its four endpoints to form a DNA tetrahedron controllable lactoferrin assembly (TAL) with a stable spatial structure, thereby effectively improving its immune activation efficiency while reducing the LF dosage; another purpose of the present invention is to provide a method for preparing a DNA tetrahedron controllable lactoferrin assembly to stably synthesize the target product; another purpose of the present invention is to provide an application of a DNA tetrahedron controllable lactoferrin assembly as an immune adjuvant in tumor immunotherapy.
[0006] Technical solution: The DNA tetrahedral lactoferrin controllable assembly of the present invention comprises a DNA tetrahedral framework and lactoferrin with an amino acid sequence shown in SEQ ID NO.5, wherein the DNA tetrahedral framework and the lactoferrin are connected via a lactoferrin adaptor.
[0007] Preferably, the DNA tetrahedral framework is assembled from four DNA chains of sequences shown in SEQ ID NOs. 1 to 4.
[0008] Preferably, the lactoferrin aptamer is a lactoferrin DNA aptamer with the sequence shown in SEQ ID NO.6.
[0009] The method for preparing the controllable assembly of lactoferrin of DNA tetrahedron of the present invention comprises the following steps:
[0010] (1) four DNA chains of sequences shown in SEQ ID NOs. 1 to 4 were mixed in equal molar proportions to construct a DNA tetrahedral framework;
[0011] (2) assembling a lactoferrin aptamer on the DNA tetrahedral framework to obtain a DNA tetrahedral framework-aptamer;
[0012] (3) Connecting the DNA tetrahedron framework-aptamer to the lactoferrin to obtain a controllable assembly of DNA tetrahedron and lactoferrin.
[0013] Preferably, in step (1) and step (2), the conditions for constructing the DNA tetrahedral framework and assembling the aptamer on the DNA tetrahedral framework are: mixing the reactants in a TM buffer, treating at 94-96° C. for 4-6 minutes, cooling to 3-5° C. for 18-22 minutes. The TM buffer formula is: 0.5M Tris-HCl (pH 7.5), 80mM MgSO4 (1×TM).
[0014] Preferably, in step (2), the lactoferrin aptamer sequence is as shown in SEQ ID NO.6.
[0015] Preferably, based on the amount of a single DNA chain added in step (1), in step (2), the amount of lactoferrin aptamer added is 4 to 6 equivalents.
[0016] Preferably, the method for connecting the DNA tetrahedral framework-aptamer and the lactoferrin is: placing lactoferrin and the DNA tetrahedral framework-aptamer in a TM buffer solution, and incubating them on a shaker at 35-39° C. and 200 rpm for 1-3 hours.
[0017] Preferably, in step (3), the amount of lactoferrin added is 2 to 6 equivalents based on the amount of a single DNA chain added in step (1).
[0018] The above-mentioned DNA tetrahedral lactoferrin controllable assembly is used for preparing adjuvants or anti-tumor drugs for enhancing tumor immunotherapy.
[0019] Preferably, the tumor is one or more of melanoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, lung cancer, liver cancer, esophageal cancer, pancreatic cancer, brain cancer, blood cancer, lymphoma, and bile duct cancer.
[0020] Preferably, the anti-tumor drug is a dual-dose drug of a combination of a controllable DNA tetrahedron lactoferrin assembly and an anti-tumor drug, the molar ratio of the controllable DNA tetrahedron lactoferrin assembly and the anti-tumor drug is 1:1-10, and the anti-tumor drug is at least one of a chemotherapy drug, a radiotherapy drug, a small molecule targeted drug, a photosensitizer, a photothermal agent and an immunotherapy drug.
[0021] Preferably, the chemotherapy drug is at least one of doxorubicin, mitomycin, bleomycin, mitoxantrone, cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin, and chlorin (Ce6).
[0022] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: 1. Improving the immune activity of lactoferrin and significantly reducing the dosage of LF: the DNA tetrahedral framework and the controllable assembly of lactoferrin significantly enhance the antigen presentation ability of free lactoferrin to macrophages RAW264.7, improve the maturity of DC, and activate the immune system. In vitro DC experiments show that the dosage of LF can be reduced to 1 / 15 of the original optimal dosage; 2. Improving the efficacy of anti-tumor drugs: the product obtained by the present invention is further used as a tumor immunotherapy adjuvant to enhance the immunotherapy effect of tumor drugs. The product obtained by the present invention is used in combination with doxorubicin (DOX) to reduce the dosage of DOX to 1 / 10 to 1 / 8 of the original recommended dosage (3 mg / kg); 3. The product obtained by the present invention is conducive to expanding the application scope of lactoferrin as an adjuvant in tumor immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1The gel electrophoresis results of different samples during the TA synthesis preparation process;
[0024] Figure 2 The gel electrophoresis results of different samples during the TAL synthesis preparation process;
[0025] Figure 3 The results show the effect of TAL on the production of nitric oxide (NO) in macrophage RAW264.7 cells;
[0026] Figure 4 The results show the effect of TAL on the secretion level of pro-inflammatory cytokine IL-6 in macrophages RAW264.7;
[0027] Figure 5 The results show the effect of TAL on the secretion level of pro-inflammatory cytokine TNF-α in macrophage RAW264.7 cells;
[0028] Figure 6 The results show the effect of TAL on the maturation of mouse bone marrow-derived dendritic cells;
[0029] Figure 7 The results show the effect of TAL on the secretion level of pro-inflammatory cytokine IL-6 in the serum of mice after treatment;
[0030] Figure 8 The results show the effect of TAL on the secretion level of pro-inflammatory cytokine TNF-α in the serum of mice after treatment;
[0031] Fig. 9 The results show the effect of TAL combined with DOX on the tumor growth curve of 4T1 tumor-bearing mice;
[0032] Fig.10 The results of TAL combined with DOX treatment on tumor size in 4T1 tumor-bearing mice;
[0033] Fig.11 These are the results of the effect of combined TAL and DOX treatment on tumor-infiltrating cytotoxic T cells in 4T1 tumor-bearing mice. DETAILED DESCRIPTION
[0034] The technical solution of the present invention is further described below in conjunction with the accompanying drawings.
[0035] Lactoferrin was provided by Sigma-Aldrich (Shanghai) Trading Co., Ltd., specific sequence nucleic acid was provided by Sangon Biotech (Shanghai) Co., Ltd., mouse macrophage cell line RAW264.7 was purchased from Jiangsu Keygen Biotech Co., Ltd., TNF-α and IL-6 cytokine ELISA detection kits were purchased from Suzhou Sibozheng Biotechnology Co., Ltd., CD80 and CD86 flow cytometry antibodies were purchased from Dakoway Biotechnology Co., Ltd., and experimental mice were purchased from Nanjing Cavens Biotechnology Co., Ltd.
[0036] Example 1: TAL synthesis and characterization
[0037] 1.1TAL synthesis
[0038] (1) DNA framework: The four DNA chains of sequences shown in SEQ ID NOs. 1 to 4 were placed in a 0.5 M Tris-HCl (pH 7.5) and 80 mM MgSO4 (1×TM) buffer solution at a molar ratio of 1:1:1:1, treated at 95°C for 4 min, and then slowly cooled to 4°C for 20 min to obtain a DNA tetrahedron framework solution (DNA-Tetrahedron, hereinafter referred to as T).
[0039] SEQ ID NO.1(A26):
[0040] GACGTCATCTTGCCTAAGCCTGGAGATACATGCACATTACGGCTTCCCTATTAG AAGGTCTCAGGTGCGCGTTCGGTAAGTAGACGGGACCAGTTCGCC
[0041] SEQ ID NO.2(B26):
[0042] GACGTCATCTTGCCTAACGCGCACCTGAGACCTTCTAATAGGGTTGCGACAGT CGTTCAACTAGAATGCCCTTGGGCTGTTCCGGGTGTGGCTCGTCGG
[0043] SEQ ID NO.3 (C26):
[0044] GACGTCATCTTGCCTAAGGCCGAGGACTCCTGCTCCGCTGCGGTTGGCGAACT GGTCCCGTCTACTTACCGTTCCGACGAGCCACACCCGGAACAGCCC
[0045] SEQ ID NO.4(D26):
[0046] GACGTCATCTTGCCTAAGCCGTAATGTGCATGTATCTCCAGGCTTCCGCAGCG GAGCAGGAGTCCTCGGCCTTGGGCATTCTAGTTGAACGACTGTCGC
[0047] (2) Based on the amount of the single DNA chain added in step (1), 4 equivalents of lactoferrin aptamer (Aptamer, dissolved in TM buffer solution and then added) with the nucleic acid sequence shown in SEQ ID NO. 6 are added to the DNA tetrahedral framework solution obtained in step (1), treated at 95° C. for 4 min, and then slowly cooled to 4° C. and treated for 20 min; a DNA tetrahedral framework-aptamer (DNA-Tetrahedron-Aptamer, hereinafter referred to as TA) solution is obtained, which is temporarily stored at 4° C. for 1 to 3 weeks or long-term stored at -20° C.
[0048] SEQ ID NO.6 (Aptamer):
[0049] AGGCAAGATGACGTCATGGCAGGACACCGTAACACGGGCTGATGCTCTCTTTATTTTTACCTAAATAAAGTGTCCTGC
[0050] (3) Based on the amount of DNA chain with the sequence shown in SEQ ID NO.1, 4 equivalents of lactoferrin with the amino acid sequence shown in SEQ ID NO.5 (dissolved in a small amount of PBS buffer with pH = 7.0 to 7.2 and then added) were added to the TA solution obtained in step (2), and the mixture was incubated on a shaker at 37°C and 200 rpm for 1 h to obtain a DNA tetrahedron lactoferrin controllable assembly (DNA-Tetrahedron-Aptamer-Lactoferrin, hereinafter referred to as TAL) solution, and the gel was cut and recovered, and the gel was removed to obtain TAL, which was temporarily stored at 4°C for 1 to 3 weeks or long-term stored at -20°C.
[0051] SEQ ID NO.5(LF):
[0052] MKLVFLVLLFLGALGLCLAGRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQAIAENRADAVTLDGGFIYEAGLAPYKLRPVAAEVYGTERQPRTHYYAVAVVKKGGSFQLNELQGLKSCHTGLRRTAGWNVPIGTLRPFLNWTGPPEPIEAAVARFFSASCV PGADKGQFPNLCRLCAGTGENKCAFSSQEPYFSYSGAFKCLRDGAGDVAFIRESTVFEDLSDEAERDEYELLCPDNTRKPVDKFKDCHLARVPSHAVVARSVNGKEDAIWNLLRQAQEKFGKDKSPKFQLFGSPSGQKDLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQNLRKSEE EVAARRARVVWCAVGEQELRKCNQWSGLSEGSVTCSSASTTEDCIALVLKGEADAMSLDGGYVYTAGKCGLVPVLAENYKSQQSSDPDPNCVDRPVEGYLAVAVVRRSDTSLTWNSVKGKKSCHTAVDRTAGWNIPMGLLFNQTGSCKFDEYFSQSCAPGSDPRSNLCALCIGDEQG ENKCVPNSNERYYGYTGAFRCLAENAGDVAFVKDVTVLQNTDGNNNEAWAKDLKLADFALLCLDGKRKPVTEARSCHLAMAPNHAVVSRMDKVERLKQVLLHQQAKFGRNGSDCPDKFCLFQSETKNLLFNDNTECLARLHGKTTYEKYLGPQYVAGITNLKKCSTSPLLEACEFLRK
[0053] 1.2 TAL characterization
[0054] The preparation of TAL was verified by gel electrophoresis. The specific implementation scheme is as follows:
[0055] In order to verify the T and TA synthesized in steps (1) and (2), and the TAL synthesized in step (3), the samples were added to the pores of 1% agarose gel, 1×TBE buffer was poured as the electrolysis buffer, and the voltage was 90V for electrophoresis for 30 to 50 minutes. After the electrophoresis, the DNA was stained with Gel-red dye, the protein was stained with Coomassie blue, and the samples were placed in a gel imager for observation.
[0056] Figure 1This is the DNA staining gel electrophoresis diagram of the synthetic sample in step (1). Referring to the size position of the DNA marker, as the number of single-stranded assemblies increases, the band position gradually moves up, verifying the successful preparation of T and TA.
[0057] Figure 2 This is the protein staining gel electrophoresis of the sample synthesized in step (3). As the ratio of LF to TA framework increases, the electrophoresis bands gradually become clearer and more delayed, verifying the successful preparation of TAL.
[0058] Example 2: The effect of TAL on the NO content produced by RAW264.7 was studied by Griess experiment. The specific implementation scheme is as follows:
[0059] After RAW264.7 was resuspended into a cell suspension, the cell concentration was adjusted to 5×10 5 / mL, 100μL cell suspension was added to a 96-well plate, and the supernatant was discarded after overnight culture. The control (blank control) group was added with 10μL (1×PBS) + 90μL (containing dual-antibody high-glucose DMEM medium), the LF control group was added with 10μL (40μM LF) + 90μL (containing dual-antibody high-glucose DMEM medium), the TA control group was added with 10μL (10μM TA) + 90μL (containing dual-antibody high-glucose DMEM medium); the T+LF control group was added with 10μL (40μM LF + 10μMT, without Aptamer) + 90μL (containing dual-antibody high-glucose DMEM medium); the TAL experimental group was added with 10μL (10μM TAL) + 90μL (containing dual-antibody high-glucose DMEM medium). Six duplicate wells were set for the control group and the experimental group respectively. Then, incubate in a 37°C, 5% CO2 incubator for 24 hours, take 50 μL of supernatant from each well and add it to another 96-well culture plate, then add a nitric oxide detection kit (50 μL Griess Reagent I and 50 μL Griess Reagent II) to each well, gently shake the culture plate to mix, and detect the absorbance value at a wavelength of 540 nm with an enzyme-labeled instrument.
[0060] Classically activated M1 macrophages produce toxic NO. NO in cells usually exists in the form of nitrite and nitrate. In this experiment, nitrate reductase is used to reduce nitrate to nitrite, and then the Griess method is used to detect the nitrite content, thereby measuring the NO concentration.
[0061] Figure 3 The following is the experimental data of the medication in different groups of the Griesss experiment, where *** is the t-test result, indicating a significant difference from the control group. Figure 3It can be seen that TAL with a final concentration of 1 μM effectively promotes RAW264.7 to produce NO, indicating that TAL with a final concentration of 1 μM can polarize RAW264.7 to the M1 phenotype.
[0062] Example 3: Determine the effect of TAL at a final concentration of 1 μM on the secretion level of the inflammatory cytokine IL-6 in RAW264.7. The specific implementation scheme is as follows:
[0063] (1) Take RAW264.7 cells with good growth status and prepare a cell suspension. Adjust the final cell concentration to 5×10 5 2000 μL of cell suspension was added to each well of a 6-well plate and the plate was incubated at 37°C and 5% CO2 until adherence.
[0064] (2) Similar to Example 2, the final concentration of TAL in the experimental group was set to 1 μM, and a control group was set up, including PBS blank control, LF, TA, and T+LF control, and three parallel wells were set up in each group. After adding the drug and incubating in a 37°C and 5% CO2 incubator for 24 hours, the supernatant was collected, and the secretion level of the inflammatory cytokine IL-6 in the cell supernatant was detected using an ELISA kit, and the absorbance of each well was measured at 450 nm on an ELISA reader.
[0065] Figure 4 The results of the secretion level of the inflammatory cytokine IL-6 are shown in Figure 4, where *** is the result of the t-test, indicating a significant difference from the control group. It can be seen that TAL at a final concentration of 1 μM can significantly promote the release of a large amount of inflammatory cytokine IL-6 by macrophages RAW264.7, proving that TAL can promote the release of pro-inflammatory factors by macrophages.
[0066] Example 4: Determine the effect of TAL at a final concentration of 1 μM on the secretion level of inflammatory cytokine TNF-α in RAW264.7. The specific implementation scheme is as follows:
[0067] (1) Take RAW264.7 cells with good growth status and prepare a cell suspension. Adjust the final cell concentration to 5×10 5 2000 μL of cell suspension was added to each well of a 6-well plate and the plate was incubated at 37°C and 5% CO2 until adherence.
[0068] (2) Similar to Example 2, the final concentration of TAL in the experimental group was set to 1 μM, and a control group was set up, including a PBS blank control, LF, TA, and T+LF controls, and three parallel wells were set up in each group. After adding the drug and incubating in a 37°C and 5% CO2 incubator for 24 hours, the supernatant was collected, and the level of inflammatory cytokine TNF-α in the cell supernatant was detected using an ELISA kit, and the absorbance of each well was measured at 450 nm on an ELISA reader.
[0069] Figure 5 The results of the secretion level of the inflammatory cytokine TNF-α are shown in Figure 4, where *** is the result of the t-test, indicating a significant difference from the control group. It can be seen that TAL at a final concentration of 1 μM can significantly promote the release of a large amount of inflammatory cytokine TNF-α by macrophages RAW264.7, proving that TAL can promote the release of pro-inflammatory factors by macrophages.
[0070] Example 5: Determine the effect of TAL at a final concentration of 1 μM on the maturation of bone marrow-derived dendritic cells. The specific implementation scheme is as follows:
[0071] Fresh cells extracted from mouse bone marrow were used as raw materials, treated with red blood cell lysis solution for 2 minutes, centrifuged to remove the supernatant, and resuspended in culture medium. Similar to Example 2, the final concentration of the TAL experimental group was 1 μM, and a control group was set up at the same time, including PBS blank control, LF, TA, and T+LF controls, and three parallel wells were set up for each group. After incubation for 24 hours, the cells were recollected, and the expression of CD80 and CD86 was analyzed by flow cytometry, and the bar graph was drawn as follows.
[0072] Figure 6 The flow cytometry clustering diagram of cells labeled with CD11c, CD80, and CD86 antibodies, where *** is the t-test result, indicating a significant difference from the control group. The experimental results show that 1 μM TAL can significantly promote the maturation of bone marrow-derived dendritic cells.
[0073] Example 6: Determination of the effect of TAL on the secretion level of pro-inflammatory cytokine IL-6 in the serum of mice after treatment. The specific implementation scheme is as follows:
[0074] (1) The experimental mice were divided into five groups, namely PBS Ctrl, LF, TA, T+LF, and TAL. The experimental mice were intraperitoneally administered with the following dosages: PBS Ctrl (100 μL, PBS), LF (100 μL, LF: 40 μM), TA (100 μL, TA: 10 μM), T+LF (100 μL, LF+T: 40 μM+10 μM), and TAL (100 μL, TAL: 10 μM). The drugs were administered every 3 days. After three administrations, orbital peripheral blood was collected and kept at 4°C for 30 min, and obvious stratification was observed.
[0075] (2) The supernatant was collected and the secretion level of the pro-inflammatory cytokine IL-6 in the cell supernatant was detected using an ELISA kit, and the absorbance of each well was measured at 450 nm on an enzyme-labeled instrument.
[0076] Figure 7 The figure shows the results of the pro-inflammatory cytokine IL-6 in mouse serum, where *** is the result of the t-test, indicating a significant difference from the control group. It can be seen that TAL effectively stimulates mouse immunity, promotes immune cells to secrete the pro-inflammatory cytokine IL-6, and enhances antigen presentation ability.
[0077] Example 7: Determination of the effect of TAL on the secretion level of pro-inflammatory cytokine TNF-α in the serum of mice after treatment. The specific implementation scheme is as follows:
[0078] (1) Grouping and dosage The same as in Example 6 were used to administer the drug intraperitoneally to the experimental mice. After three doses, orbital peripheral blood was collected and allowed to stand at 4°C for 30 minutes, and obvious stratification occurred.
[0079] (2) The supernatant was collected and the secretion level of the pro-inflammatory cytokine TNF-α in the cell supernatant was detected using an ELISA kit, and the absorbance of each well was measured using an enzyme marker (450 nm).
[0080] Figure 8 The results of TNF-α content in mouse serum are shown in Figure 2, where *** is the result of t-test, indicating significant difference from the control group. It can be seen that TAL effectively stimulates the immune system of mice, promotes immune cells to secrete pro-inflammatory cytokine TNF-α, and enhances antigen presentation ability.
[0081] Combined with the above analysis results, it can be seen that TAL can effectively activate macrophages, polarize macrophages to M1 phenotype, and enhance the secretion of pro-inflammatory cytokines. At the same time, TAL can also promote the maturation of bone marrow-derived dendritic cells, promote the activation of the body's immune system, enhance the ability of cross-antigen presentation, and effectively improve the immunotherapy effect of cancer.
[0082] Example 8: Study on the combination of TAL and DOX (doxorubicin) to enhance the immunotherapy results of 4T1 tumor-bearing mice. The specific implementation plan is as follows:
[0083] (1) 4T1 tumor cells were inoculated into the chest of experimental mice and the tumor volume was cultured to 80-100 mm 3Start drug treatment. Set up PBS blank control group, LF group, TA group, T+LF group and TAL group respectively, each group was injected with 200μM, 50μL of DOX chemotherapy drug into the tumor (calculated according to the weight of the mouse, the DOX dosage was 300ug / kg), and 24h later, PBS, LF, TA, T+LF, TAL drugs were injected respectively, and the dosage of PBS, LF, TA, T+LF, TAL in each group was the same as that in Example 6. A total of three treatment cycles were performed, with an interval of 24h between cycles, and the rest remained the same except for the treatment drugs. The tumor growth size of mice during the treatment cycle is as follows Fig. 9 As shown in the figure, the combination of TAL and DOX can effectively enhance the inhibitory effect of DOX on tumor growth and enhance the immunotherapy effect. The experiment found that TAL had no obvious killing effect on 4T1 tumors.
[0084] (2) The mice were euthanized, the solid tumors were removed and photographed, and the size of the solid tumors was as follows: Fig.10 As shown, TAL combined with DOX effectively inhibited 4T1 tumor growth.
[0085] (3) Solid tumors were sampled, ground to prepare cell suspensions, and flow cytometry was performed. The flow cytometry results were as follows: Fig.11 As shown, TAL can effectively enhance the recruitment of cytotoxic T cells at the tumor site: by stimulating macrophage M1 polarization to phagocytize tumor cells to provide antigens, and promoting DC cell maturation to present antigens to activate T cells to recruit to tumor tissues to complete the process of killing tumors.
Claims
1. A controllable assembly of lactoferrin of DNA tetrahedron, characterized in that: The invention relates to lactoferrin comprising a DNA tetrahedral framework and an amino acid sequence shown in SEQ ID NO.5, wherein the DNA tetrahedral framework and the lactoferrin are connected via a lactoferrin adaptor.
2. The controllable lactoferrin assembly of DNA tetrahedron according to claim 1, characterized in that: The DNA tetrahedron framework is formed by assembling four DNA chains of sequences shown in SEQ ID NOs. 1 to 4.
3. The controllable lactoferrin assembly of DNA tetrahedron according to claim 1 or 2, characterized in that: The lactoferrin aptamer is a lactoferrin DNA aptamer with a sequence shown in SEQ ID NO.
6.
4. A method for preparing a controllable lactoferrin assembly of DNA tetrahedrons according to any one of claims 1 to 3, characterized in that: The following steps are involved: (1) Mix four DNA chains in equal molar proportions to construct a DNA tetrahedral framework; (2) assembling a lactoferrin aptamer on the DNA tetrahedral framework to obtain a DNA tetrahedral framework-aptamer; (3) Connecting the DNA tetrahedron framework-aptamer to the lactoferrin to obtain a controllable assembly of DNA tetrahedron and lactoferrin.
5. The preparation method according to claim 4, characterized in that: In step (1) and step (2), the conditions for constructing the DNA tetrahedral framework and assembling the aptamer on the DNA tetrahedral framework are: mixing the reactants in TM buffer, treating at 94-96° C. for 4-6 minutes, cooling to 3-5° C. for 18-22 minutes.
6. The preparation method according to claim 5, characterized in that: Based on the amount of a single DNA chain added in step (1), in step (2), the amount of lactoferrin aptamer added is 4 to 6 equivalents.
7. The preparation method according to claim 4, characterized in that: In step (3), the method for connecting the DNA tetrahedral framework-aptamer and the lactoferrin is as follows: lactoferrin and the DNA tetrahedral framework-aptamer are placed in a TM buffer solution and incubated at 35-39° C. and 200 rpm on a shaker for 1-3 hours.
8. The preparation method according to claim 7, characterized in that: Based on the amount of a single DNA chain added in step (1), in step (3), the amount of lactoferrin added is 2 to 6 equivalents.
9. Use of the lactoferrin controllable assembly of DNA tetrahedrons according to any one of claims 1 to 3 in the preparation of an adjuvant or anti-tumor drug for enhancing tumor immunotherapy, wherein the tumor is one or more of melanoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, lung cancer, liver cancer, esophageal cancer, pancreatic cancer, brain cancer, blood cancer, lymphoma, and bile duct cancer.
10. The use according to claim 9, wherein the anti-tumor drug is a dual-dose drug composed of a controllable DNA tetrahedron lactoferrin assembly and an anti-tumor drug, the molar ratio of the controllable DNA tetrahedron lactoferrin assembly and the anti-tumor drug is 1:1-10, and the anti-tumor drug is at least one of a chemotherapy drug, a radiotherapy drug, a small molecule targeted drug, a photosensitizer, a photothermal agent and an immunotherapy drug.
